Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors In Elderly Patients With Malignant Pleural Mesothelioma: Results Of A Multicenter Survey

G. Ceresoli, F. Grosso, P. Zucali, M. Mencoboni, G. Pasello, Cristina Ripa, D. Degiovanni, M. Simonelli, A. Bruzzone, C. Dipietrantonj, E. Piccolini, G. Beretta, A. Favaretto, L. Giordano, A. Santoro, M. Botta
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background:The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. There are no specific guidelines for their management.Methods:The clinical records of elderly patients (⩾70 years old) with MPM referred from January 2005 to November 2011 to six Italian Centres were reviewed. Age, gender, histology, International Mesothelioma Interest Group (IMIG) stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) and treatment modalities were analysed and correlated to overall survival (OS).Results:In total, 241 patients were identified. Charlson Comorbidity Index was ⩾1 in 92 patients (38%). Treatment was multimodality therapy including surgery in 18, chemotherapy alone in 180 (75%) and best supportive care in 43 cases (18%). Chemotherapy was mainly pemetrexed based. Median OS was 11.4 months. Non-epithelioid histology (HR 2.32; 95% CI 1.66–3.23, P<0.001), age ⩾75 years (HR 1.44; 95% CI 1.08–1.93, P=0.014), advanced (III–IV) stage (HR 1.47; 95% CI 1.09–1.98, P=0.011) and CCI⩾1 (HR 1.38; 95% CI 1.02–1.85, P=0.034) were associated to a shorter OS. Treatment with pemetrexed was associated with improved OS (HR 0.40; 95% CI 0.28–0.56, P<0.001).Conclusions:Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM. Treatment with pemetrexed-based chemotherapy was feasible in this setting. Prospective dedicated trials in MPM elderly patients selected according to prognostic factors including comorbidity scales are warranted.
This paper references
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1038/bjc.2012.245
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij (2012)
10.1016/0197-2456(96)00075-X
A note on quantifying follow-up in studies of failure time.
M. Schemper (1996)
BRITISH JOURNAL OF CANCER Prognostic factors in elderly patients with MPM
10.1016/0021-9681(87)90171-8
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M. Charlson (1987)
10.1016/j.ctrv.2009.04.005
Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool.
A. Brunello (2009)
10.1002/ijc.26229
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
10.1007/s00280-013-2142-9
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Y. Kim (2013)
10.1186/1471-2407-4-94
An electronic application for rapidly calculating Charlson comorbidity score
W. Hall (2004)
10.1016/S1470-2045(01)00626-X
The European Organisation for Research and Treatment of Cancer
R. Camidge (2002)
10.1016/j.cllc.2011.12.002
Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
Cesare Gridelli (2012)
10.1002/ajim.22206
Potential years of life lost (PYLL) caused by asbestos-related diseases in the world.
Rachmania Diandini (2013)
A (2013) Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
GL Ceresoli (2013)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1136/oem.2006.031823
Projected mesothelioma incidence in men in New South Wales
M. Clements (2007)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1093/annonc/mdq687
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors.
A. Pallis (2011)
10.1038/nrc3497
How ageing processes influence cancer
J. P. Magalhães (2013)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1016/S1470-2045(12)70259-0
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review.
M. Hamaker (2012)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1016/J.JCLINEPI.2005.11.013
A user's guide to selecting a comorbidity index for clinical research.
S. Hall (2006)
10.1002/SIM.5511
Contrasting treatment‐specific survival using double‐robust estimators
K. Kim (2012)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.2471/BLT.11.086678
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
V. Delgermaa (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/j.lungcan.2013.01.008
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
Radj Gervais (2013)
10.1016/j.semradonc.2012.05.003
Integrating a geriatric evaluation in the clinical setting.
M. Extermann (2012)
J Clin Oncol
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
( NSCLC ) : a phase II trial
C Gridelli (2012)
European Organisation for Research and Treatment of Cancer Elderly
AG Pallis (2011)
10.1200/JCO.2007.10.6567
Geriatric oncology: a field coming of age.
S. Lichtman (2007)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
Pleural mesothelioma: epidemiological and public health issues. Report from the Second Italian Consensus Conference on Pleural Mesothelioma.
C. Magnani (2013)
European Organisation for Research and Treatment of Cancer Elderly Task Force (2011) EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumours
A G Pallis
Prognostic factors in elderly patients with MPM BRITISH JOURNAL OF CANCER www
10.1016/j.semradonc.2012.05.002
Impact of age and comorbidity on treatment and outcomes in elderly cancer patients.
R. Chen (2012)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.2486/INDHEALTH.MS1184
Future trends of mesothelioma mortality in Japan based on a risk function.
Tomoya Myojin (2012)



This paper is referenced by
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.2147/OTT.S115631
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma
Manal El-Hamamsy (2016)
10.18632/oncotarget.17436
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
Long Tian (2017)
10.1002/cam4.1378
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
C. Chouaid (2018)
10.1159/000464410
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
M. Mencoboni (2017)
10.1016/j.cllc.2017.01.008
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma
Shinkichi Takamori (2017)
10.1016/j.jgo.2019.02.013
Patterns of care and survival of older patients with malignant pleural mesothelioma.
Anthony Linton (2019)
10.2147/OTT.S134126
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma
K. Aigner (2017)
10.1016/j.jtho.2015.10.003
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
10.1111/1759-7714.13456
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
A. Trama (2020)
10.1371/journal.pone.0229299
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma
Jun Hyeok Lim (2020)
10.1016/j.cllc.2016.03.002
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
C. Yang (2016)
10.1016/j.lungcan.2017.08.009
Patterns of care and survival among patients with malignant mesothelioma in the United States.
L. Enewold (2017)
10.1093/ejcts/ezw215
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Maurizio Infante (2016)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1007/978-3-662-48727-3_39
Pleuramesotheliom beim alten und geriatrischen Patienten
Martin Steins (2018)
10.1080/00015458.2016.1272253
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period
A. Domen (2017)
10.1016/j.ctrv.2015.10.006
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Giovanni Luca Ceresoli (2015)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations
(2016)
10.1080/2162402X.2018.1564452
CD8+ cytotoxic T cell responses to dominant tumor-associated antigens are profoundly weakened by aging yet subdominant responses retain functionality and expand in response to chemotherapy
C. Jackaman (2019)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Giovanni Luca Ceresoli (2019)
10.1245/s10434-018-6385-x
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study
Shinkichi Takamori (2018)
10.12816/0042979
A Retrospective Analysis of Epidemiology Prognostic Factor and Response of Treatment of Malignant Pleural Mesothelioma
Dalia Abd El-Ghany El-Khodary (2018)
Semantic Scholar Logo Some data provided by SemanticScholar